Genentech's Giredestrant is the First Oral SERD to Demonstrate Enhanced Invasive Disease-Free Survival in Early Breast Cancer

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 18 2025

0mins

Source: Yahoo Finance

Positive Phase III Results: Giredestrant showed a statistically significant improvement in invasive disease-free survival compared to standard endocrine therapy in early-stage ER-positive, HER2-negative breast cancer, marking it as a potential new standard of care.
Clinical Development and Safety: The drug was well tolerated with no unexpected safety issues, and its efficacy is supported by previous trials, indicating a promising future for giredestrant in various treatment settings for breast cancer.
Need for Better Treatment Options: With ER-positive breast cancer accounting for about 70% of cases, there is a critical need for more effective and tolerable treatments to reduce recurrence and improve patient outcomes.
Upcoming Data Presentation: Results from the lidERA study will be presented at a medical meeting and shared with health authorities globally to facilitate access to this potential new treatment option for patients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.